NO20041449L - Krystallinformer av valasyklovir-hydroklorid - Google Patents

Krystallinformer av valasyklovir-hydroklorid

Info

Publication number
NO20041449L
NO20041449L NO20041449A NO20041449A NO20041449L NO 20041449 L NO20041449 L NO 20041449L NO 20041449 A NO20041449 A NO 20041449A NO 20041449 A NO20041449 A NO 20041449A NO 20041449 L NO20041449 L NO 20041449L
Authority
NO
Norway
Prior art keywords
valacyclovir hydrochloride
crystal information
crystal
information
valacyclovir
Prior art date
Application number
NO20041449A
Other languages
English (en)
Norwegian (no)
Inventor
Judith Aronhime
Ben-Zion Dolitzky
Shlomit Wizel
Valerie Niddam-Hildesheim
Marina Yu Etinger
Michael Yuzefovich
Gennady A Nisnevich
Boris Pertsikov
Boris Tishin
Dina Blasberger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20041449L publication Critical patent/NO20041449L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
NO20041449A 2001-09-07 2004-04-06 Krystallinformer av valasyklovir-hydroklorid NO20041449L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31785001P 2001-09-07 2001-09-07
US34227301P 2001-12-21 2001-12-21
US38650502P 2002-06-05 2002-06-05
US40383802P 2002-08-14 2002-08-14
PCT/US2002/028517 WO2003022209A2 (fr) 2001-09-07 2002-09-06 Formes cristallines de chlorhydrate de valacyclovir

Publications (1)

Publication Number Publication Date
NO20041449L true NO20041449L (no) 2004-04-06

Family

ID=27502150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041449A NO20041449L (no) 2001-09-07 2004-04-06 Krystallinformer av valasyklovir-hydroklorid

Country Status (16)

Country Link
US (2) US6849736B2 (fr)
EP (1) EP1436295A4 (fr)
JP (2) JP5043286B2 (fr)
KR (1) KR100774271B1 (fr)
CN (1) CN1551880A (fr)
CA (1) CA2457835A1 (fr)
CZ (1) CZ2004446A3 (fr)
HR (1) HRP20040321A2 (fr)
HU (1) HUP0500753A3 (fr)
IL (1) IL160721A0 (fr)
IN (2) IN2004MU00133A (fr)
MX (1) MXPA04002192A (fr)
NO (1) NO20041449L (fr)
PL (1) PL374179A1 (fr)
SK (1) SK1592004A3 (fr)
WO (1) WO2003022209A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453834A1 (fr) * 2001-11-05 2004-09-08 Glaxo Group Limited Forme cristalline anhydre du valaciclovir chlorhydrate
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
WO2004000265A2 (fr) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Procede de preparation de formulations solides de comprimes de chlorhydrate de valacyclovir
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ES2270172T3 (es) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
DE60301277T2 (de) * 2003-12-09 2006-03-30 Helm Ag Pharmazeutische zubereitung enthaltend valaciclovir
CN1976933A (zh) * 2004-06-30 2007-06-06 特瓦制药工业有限公司 减少晶体盐酸伐昔洛韦中的残留醇的方法
WO2006035452A1 (fr) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Nouveau pseudomorphe d'hydrochlorure de valaciclovir
EP1746098A1 (fr) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Des polymorphes de valacyclovir et procédé pour leur fabrication
US7872075B2 (en) * 2005-10-07 2011-01-18 Exxonmobil Chemical Patents Inc. Peroxide-cured thermoplastic vulcanizates and process for making the same
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
WO2011158252A1 (fr) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Méthode de préparation de la forme polymorphe ii du chlorhydrate de valacyclovir
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
TWI788702B (zh) 2013-11-15 2023-01-01 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
AU6854694A (en) * 1993-06-10 1995-01-03 Farmhispania Sa Amino acid ester of nucleoside analogues
US5856481A (en) * 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
JP4097698B2 (ja) * 1996-01-19 2008-06-11 グラクソ、グループ、リミテッド 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP1453834A1 (fr) * 2001-11-05 2004-09-08 Glaxo Group Limited Forme cristalline anhydre du valaciclovir chlorhydrate
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
WO2004000265A2 (fr) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Procede de preparation de formulations solides de comprimes de chlorhydrate de valacyclovir
WO2004052892A1 (fr) * 2002-12-09 2004-06-24 Texcontor Etablissement Forme cristalline anhydre d'hydrochlorure de valacyclovir
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1746098A1 (fr) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Des polymorphes de valacyclovir et procédé pour leur fabrication
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Also Published As

Publication number Publication date
EP1436295A2 (fr) 2004-07-14
HUP0500753A2 (hu) 2005-11-28
EP1436295A4 (fr) 2007-07-11
JP2012162565A (ja) 2012-08-30
US20050187229A1 (en) 2005-08-25
JP2005526694A (ja) 2005-09-08
MXPA04002192A (es) 2005-02-17
US6849736B2 (en) 2005-02-01
CN1551880A (zh) 2004-12-01
WO2003022209A3 (fr) 2003-11-27
WO2003022209A2 (fr) 2003-03-20
HUP0500753A3 (en) 2006-05-29
KR100774271B1 (ko) 2007-11-08
KR20040036932A (ko) 2004-05-03
CZ2004446A3 (cs) 2005-01-12
WO2003022209A9 (fr) 2004-04-08
PL374179A1 (en) 2005-10-03
IN2006MU00429A (fr) 2007-08-17
IN2004MU00133A (fr) 2005-04-29
HRP20040321A2 (en) 2004-08-31
JP5043286B2 (ja) 2012-10-10
US20030114470A1 (en) 2003-06-19
IL160721A0 (en) 2004-08-31
CA2457835A1 (fr) 2003-03-20
SK1592004A3 (sk) 2005-03-04

Similar Documents

Publication Publication Date Title
NO20041449L (no) Krystallinformer av valasyklovir-hydroklorid
FI20011089A (fi) Informaation kommunikointi
NO20035177D0 (no) Krystallformer av Azithromycin
DK1438306T3 (da) Derivater af UK-2A
DE60236226D1 (de) Verbesserung der Altersweitsichtigkeit
DE60233399D1 (de) Erzerrung zweiter ordnung
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
ATE437871T1 (de) Polymorphe formen von 1-ä4-(5-cyanoindol-3- yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid
DK1470732T3 (da) Fremskaffelse af lokaliseringsinformation
NO20041968L (no) Anvendelse av cystationin
DE60222983D1 (de) Serieller Datenzeiger
DE60227828D1 (de) E von schmelzkleber
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
DE60131666D1 (de) Höhenmessgerät
IS6884A (is) Aðferðir við að nýta líffræðilegan fjölbreytileika
DE60131182D1 (de) Höhenmessgerät
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
NO20015569L (no) Display med mikrolommer
IS7169A (is) Kristölluð form valasýklóvírhýdróklóríðs
ATE410417T1 (de) Kristallmodifikationen von triazinylaminostilbenen
ITBA20010029V0 (it) Gioiello di puglia
FI20010391A (fi) Kalanteri
NO20035297D0 (no) Fremgangsmåte for fremvisning av data
ITGE20010022U1 (it) Orologio

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application